

CENTERS FOR DISEASE CONTROL AND PREVENTION  
NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH (NIOSH)  
ADVISORY BOARD ON RADIATION AND WORKER HEALTH (ABRWH)  
MEETING #163

THURSDAY, FEBRUARY 19, 2026

The meeting convened at 11:00 a.m. Eastern Standard Time (EST)

Dr. Henry Anderson, Chair, presiding.

Vet Reporting  
Certified Court Reporters  
PO Box 72314  
Marietta, GA 30007  
678-646-5330 ext. 514  
[reporter@vetreporting.com](mailto:reporter@vetreporting.com)

Members Present:

Anderson, Henry, Chair  
Beach, Josie, Member  
Bronson, Fraizer, Member  
Clawson, Bradley, Member  
Frank, Arthur, Member  
Lockey, James, Member  
Martinez, Nicole, Member  
Schmoltdt, Michael, Member  
Silver, Kenneth, Member  
Vlieger, Faye, Member  
Valerio, Loretta, Member  
Ziemer, Paul, Member

Registered Participants:

Roberts, Rashaun, Designated Federal Official (DFO)  
Barton, Bob, SC&A  
Behling, Kathy, SC&A  
Buchanan, Ron, SC&A  
Holzberger, Malia, Department of Health and Human Service (HHS)  
Hughes, Lara, NIOSH  
Mangel, Amy, SC&A  
Marion-Moss, Lori, NIOSH  
Nelson, Charles, NIOSH  
Ostrow, Steve, SC&A  
Ulsh, Brant, NIOSH

Registered and/or Public Comment Participants:

DeGarmo, Denise

Hand, Donna

## TABLE OF CONTENTS

Advisory Board on Radiation and Worker Health (ABRWH) Meeting #163 ....	1
Proceedings .....	5
Welcome and Roll Call .....	5
Board Update .....	9
Program Update .....	9
Special Exposure Cohort (SEC) Status Update .....	13
Updates from Work Groups and Subcommittees.....	17
Plans for the April 2026 Board Meeting .....	21
Updates from Work Groups and Subcommittees Resuming .....	22

## PROCEEDINGS

(11:01 a.m. EST)

**WELCOME AND ROLL CALL**

DR. ROBERTS: It is 11:00 a.m., and I'm going to go ahead and wish everybody a good morning. My name is Rashaun Roberts, and I'm the Designated Federal Officer for the Advisory Board on Radiation and Worker Health, and this is the Board's 163rd meeting. The primary purpose of today's meeting is to prepare for the full Board meeting that has been tentatively scheduled for April 29th and 30th, although there are other items, mainly updates, on today's agenda.

I can still hear some background. If everybody can, make sure their phone is on mute. You can press star six to mute it if you don't have a mute button.

The agenda is posted on the NIOSH website. There is a schedule of Board meetings provided on the site, and you can access the agenda for today's meeting under the February 2026 tab. As you know, this meeting is being conducted by telephone only. If we want to keep the meeting moving forward without interruption, I ask each of you to please mute your phone unless you're talking. If you don't have a mute button, press star six to mute. If you need to take yourself off mute, press star -- star six again. Also, because we will be unable to see each other for this meeting, please identify yourself before your comments or questions.

I'm very pleased to share that we're joined today by four new members of the Board who will be included in the roll call. Please note that

they are all in listen-only mode today because there are a few more items that need to be wrapped up administratively before they're able to fully participate on the Board, which I'll describe a little later in my Board update, but the item should be wrapped up fairly soon. So, I'd like to welcome them and thank them for their patience as we get things completely buttoned up.

So, with all that said, let me move into the roll call, and I'll start with the Board members in alphabetical order. Anderson?

CHAIR ANDERSON: Present.

DR. ROBERTS: Beach?

MEMBER BEACH: I'm here.

DR. ROBERTS: Bronson?

MEMBER BRONSON: I'm here.

DR. ROBERTS: Clawson?

MEMBER CLAWSON: I'm here.

DR. ROBERTS: Frank?

MEMBER FRANK: Here.

DR. ROBERTS: Lockey?

MEMBER LOCKEY: I'm here.

MEMBER MARTINEZ: Martinez?

MEMBER MARTINEZ: I'm here.

DR. ROBERTS: Pompa?

MEMBER POMPA: Yes, ma'am, I'm here.

MEMBER SCHMOLDT: Schmoldt?

MEMBER SCHMOLDT: Here.

DR. ROBERTS: Silver?

MEMBER SILVER: Here.

DR. ROBERTS: Vlieger?

MEMBER VLIEGER: Here.

DR. ROBERTS: Valerio?

MEMBER VALERIO: I'm here.

DR. ROBERTS: And Ziemer?

MEMBER ZIEMER: I'm here.

DR. ROBERTS: Great. Sounds like a full house. We definitely have our quorum, so let me continue with the roll call. Who's here for DCAS and ORAUT?

MS. MARION-MOSS: This is Lori Marion Moss, NIOSH.

DR. NELSON: Chuck Nelson, NIOSH.

DR. ULSH: Brant Ulsh, NIOSH.

DR. HUGHES: Lara Hughes, NIOSH.

MR. GOODMAN: Justin Goodman.

DR. ROBERTS: Anyone else for DCAS or Oak Ridge Associated Universities Team (ORAUT)? Let's move on to SC&A

MR. BARTON: Bob Barton. Happy to be here.

MS. BEHLING: Kathy Behling.

DR. BUCHANAN: Ron Buchanan, conflicted with Los Alamos.

MS. MANGEL: Amy Mangel.

DR. OSTROW: Steve Ostrow.

DR. ROBERTS: Okay. Anyone else for SC&A? Okay. Is there anyone here, HHS or contractors?

MS. HOLZBERGER: Malia Holzberger, HHS/Office of General Council (OGC).

DR. ROBERTS: Okay. Hearing, no more. Are there anyone -- is there anyone here from Department of Labor (DOL) or Department of Energy (DOE) or any of the departments? Okay. Hearing none, I'd like to ask if there are any members of the public who'd like to register their attendance.

DR. DEGARMO: Dr. Denise DeGarmo, authorized petition representative for 256, 266, and 267.

DR. ROBERTS: Good morning.

MS. HAND: Donna Hand.

DR. ROBERTS: Anyone -- okay. Good morning. Anyone else? Okay. Well, thank you very much. Let's go ahead and move into the agenda. Again, please periodically check your phone to ensure that you're on mute. If there's no mute button, press star six. If you need to take yourself off, press star six again.

So, let me go ahead and I will turn the floor over to Dr. Henry Anderson, Board Chair to lead the rest of the agenda.

CHAIR ANDERSON: Thank you, Rashaun. And I really want to also give my thank you to the new members who have been very patient and at the same time have no doubt been required to produce all sorts of different documents while waiting to become full members and participating. And we're nearly there, and we thank you, and we're glad you're able to listen in, and next time, I'll be calling on you for comments. So, look forward to working with the new group, and hopefully we'll be able to get April all organized, and we'll be able to get together in -- in person before too long.

So, we've had a number of the subcommittees who have been able to meet, and so we'll hit a little bit of update on those activities. But let's move on now to Rashaun and give an update on the Board.

### **BOARD UPDATE**

DR. ROBERTS: Yes, just a really quick update. And again, I'm sure we're all very happy to have the new Board members. I mentioned that there are some remaining administrative items that we're still in the process -- process of addressing with them, including getting their computers and smart cards so that they can access all of the materials that are available to the Board. Importantly, we're also in the process of working with them to identify conflicts of interest so that they can receive the appropriate recusal guidance, and so that Andy and I can start assigning them to the appropriate work groups and subcommittees. As I said earlier, we should have these things taken care of soon, so that they can fully participate on the Board and not be in listen only mode. So, that's my update. Thanks, Andy.

### **PROGRAM UPDATE**

CHAIR ANDERSON: Okay. For those of you, I think all of the current Board members know, but Lori Marion-Moss is the new DCAS director, and we'll get a program update from her. She has sat in on a number of our subcommittee meetings, and glad to have her on board. So, Lori, take it away.

MS. MARION-MOSS: Good morning, everyone. I'll start off with an

Information Technology (IT) update. So, that you all know that DCAS is down four IT contractors that have supported us for years on this project. Their contract was not renewed, so we are currently down to two IT staff at this time. Why is that important, for some of the new members? Well, it's important because our IT supports access to DCAS applications, as well as a number of documents that support a lot of our dose reconstructions and our SEC petitions. So, I just wanted to bring everyone update on that, we're down several staff that support from an IT perspective.

I would also like to note that for those of you who do have access or will be gaining access to DCAS data, there is now a shared folder available in ORAUT's environment. This shared folder is the same shared folder that was used in the Edge Computing System (ECP) where SC&A and DCAS could share documents. This folder is available for not only SC&A and DCAS, but as well as the Board members.

Another update for IT, we are in the planning stages to continue to modernize our applications. We have most of our applications stood up in ORAUT's environment, and that -- most of them are currently in use. We're still doing some tests on others, but the main one of interest predominantly is NIOSH OCAS Claims Tracking System (NOCTS), as well as the site research database. If you do plan on reaching out and gaining access and you encounter any issues, please let me know. I think we can put in the chat here an email address that you could reach out to our NOCTS support and let us know that you're having trouble accessing the ORAUT environment.

One Note I would like to make, I note some of you are familiar with

the term CyberArk, and -- and some have used that term interchangeably to reference ORAUT's environment. But I just want to make a quick note here. CyberArk is not ORAUT's environment. It is actually the tool we use to remote over into ORAUT's environment. Okay. So, I just wanted to make that note.

Another note -- an update I would like to make is in regards to DCAS staff. In 2025, DCAS had approximately 30 staff members shared between HPs and some of our communications and our admin staff. Due to retirements and resignations, we are down to 24 personnel, and we're looking to lose at least two more this year. So, that's -- just give you a perspective of who all's available to support this program at the current time.

Next, I would like to move on to the contract update, the dose reconstruction contract. This is the largest contract we have in support of EEOICPA here at NIOSH. The current contract expires on the 26th of March of this year. Now, due to the lack of resources with contracting personnel, a request for proposal has been delayed. So, there -- we're entering into a six-month contract extension, which is underway, and we hope to get that through -- that approval through soon.

And last but not least, I would like to make a note in regards to forthcoming outreach events. These outreach events are typically hosted by the Department of Labor. We have learned that DOL has been approved to resume these events in 2026. So, far on the schedule, there will be an event on April the 14th at Savannah River Site (SRS) in Aiken, South Carolina. There's also an event scheduled at Nevada Test Site (NTS) on May

19th in Las Vegas. And then there's another on June 30th at the Oak Ridge site in Oak Ridge, Tennessee. And there's an August the 11th event scheduled at Los Alamos at Los Alamos National Laboratory (LANL). These four events, outreach events, NIOSH plans to attend and -- in support of informing the public about the program and answer any questions that they may have of NIOSH. So, we do plan on supporting and attending these events.

And Dr. Anderson, that's all I have.

CHAIR ANDERSON: Thank you very much. Just a quick question. Are you going to be able to replace any of the staff, or are we on a hiring freeze still?

MS. MARION-MOSS: Well, from what I can tell, yes, we're -- we're -- we're starting to -- the -- the hiring freeze is starting to thaw, if you will. So, we're working with HR to take a look at our hiring plans so that hopefully we can replace some of the positions that we've lost.

CHAIR ANDERSON: Wonderful. That's always good news to hear that hopefully things will -- you'll be able to fill some of the slots that are really causing delays in activities and things. And the IT support, I know, for the two folks coming on board is going to be probably critical, and they just have to remain patient when you call and leave a message, but speaking for myself, I've always been able to get prompt assistance from them, and they've always been very helpful. So, hopefully that's one of the areas we'll be able to fill up so we can all get running up top speed as well as we can.

So next up, --

MR. BARTON: Andy, this is Bob, if I might, I -- I'm very slow again,

but I -- Lori, could you repeat those dates for the -- specifically the SRS and LANL worker outreach meetings?

MS. MARION-MOSS: The SRS outreach meeting will take place on April the 14th of this year, --

MR. BARTON: Okay.

MS. MARION-MOSS: -- and the LANL is August the 11th.

MR. BARTON: And there was a third one -- I didn't catch it. Sorry.

MS. MARION-MOSS: Was it Oak Ridge?

MR. BARTON: Yes, (indiscernible). Yep.

MS. MARION-MOSS: That's scheduled for June 30th.

MR. BARTON: June 30th. Thank you so much. Again, slow hand. I was trying to find a pen. June 30th. Thank you.

MS. MARION-MOSS: Did you get the NTS one, Bob? There's also --

MR. BARTON: Oh, also --

MS. MARION-MOSS: -- on --

MR. BARTON: -- NTS, okay.

MS. MARION-MOSS: -- May -- May 19th.

MR. BARTON: 5/19. Okay. Thank you, again, Lori. Thank you.

CHAIR ANDERSON: Okay. And for the -- for the new members, you've already heard a number of acronyms and a lot of letters, titles that we use for various programs and things, and we'll -- we'll try to give you a cheat sheet on what all of these mean, and -- so you can understand how these relationships all interact.

## **SPECIAL EXPOSURE COHORT (SEC) STATUS UPDATE**

CHAIR ANDERSON: So, next up is a special exposure cohort update status by Chuck Nelson.

DR. NELSON: Yeah, Dr. Anderson, it'll be Lara. She's on 120-day detail as SEC team lead, so she will do this part for me.

CHAIR ANDERSON: Okay. I think I did see that. Sorry. Yeah.

DR. HUGHES: Okay. Can you hear me okay?

CHAIR ANDERSON: Yes.

DR. HUGHES: Okay. Thank you, Dr. Anderson. Thank you, Chuck. Good morning. So, I'm giving the SEC petition status update. This is -- going over briefly over the SEC petitions that are currently being worked at NIOSH, as opposed to the petitions that are with the Advisory Board in one way or another. So, there are currently nine petitions that are with the Advisory Board, and there are two active petitions at NIOSH.

Okay. Sorry, I've just been getting some weird echoing. One of the petitions that is active at NIOSH is undergoing the SEC evaluation, and the other petition is in the administrative review step of the qualification process. And I'm going to go over those two briefly to give you a little more detail. I assume that the work group chairs will be providing updates on the status of the petitions that are with the Board. However, we could answer any questions for NIOSH, or we -- we would attempt to answer any questions for NIOSH on those petitions as well.

Okay. So first, the first petition is SEC-266 for the Weldon Spring Plant. This petition is undergoing administrative review of the qualification process. This petition was received in July of 2025, and NIOSH reviewed the documentation submitted by the petitioner and issued the petition

qualification review in late 2025. And the outcome of this review was that the petition does not qualify for further evaluation. The -- this notice of nonqualification was sent to the petitioners and the Advisory Board, and the authorized Petitioner representative has requested an administrative review of this qualification process after the petition failed to qualify. And this request was received by NIOSH in February -- on February 3, 2026.

The administrative review request, once it's received by NIOSH, is sent to the NIOSH director, who will appoint a panel of three NIOSH scientists that will review all documentation related to the petition and then provide a report on whether or not the qualification process of this petition was followed correctly. And so -- excuse me -- this panel has 30 working days based on the regulation and expected to issue their report on March 18th. So, next month.

The next petition that is also at NIOSH is SEC-267 for the United Nuclear Corporation in Hematite, Missouri. This petition was qualified for further evaluation in late 2025, and NIOSH is currently doing research to determine if there's any infeasibilities to support adding a class to the special exposure cohort. And specifically, the current step is that NIOSH is doing interviews and collecting additional data to answer some questions related to exposures. The evaluation report is scheduled to be completed around the middle of the year.

And a little bit of background of this petition, the petitioner requested a class to be added starting in 1958 through the end of 2011. NIOSH reviewed all documentation that was submitted and qualified for evaluation the class at United Nuclear for all employees that worked from January 1958

through June 30, 1965. The reason this petition qualifies for further evaluation is because NIOSH discovered some documentation that -- during more recent work, in the 2012 to 2014 time frame, a contractor uncovered Radium-226 contaminated filter-press plates at a burial site, as I understand. And this could potentially result in some exposures. And we're currently determining whether radiation doses can be reconstructed during this time frame, when these plates were handled at the site. In addition, NIOSH submitted a letter to the Department of Energy to evaluate whether or not an extension should be added to the residual contamination period or to the residual period for the site to -- all the way to 2011.

And that is really all I have for the -- the two petitions that are currently at NIOSH. So, if you have any questions, I'll be happy to answer. Thank you.

CHAIR ANDERSON: Thank you. Board members, are there any questions? If you're speaking and you're on mute, unmute. I can't see, so I don't know who's where. If not, let's move on to --

MEMBER CLAWSON: Andy? Andy?

CHAIR ANDERSON: Yeah, go ahead.

MEMBER CLAWSON: This is Brad. Sorry, I was talking on mute. I'm just wondering about that one that's under administrative review. When that -- Lara, when that goes through, and it goes through the administrative review, is there going to be a report that's going to be given to you and also the Advisory Board, so we'll know what the status is and why?

DR. HUGHES: Yes.

MEMBER CLAWSON: Okay. Thank you.

CHAIR ANDERSON: Any other questions?

### **UPDATES FROM WORK GROUPS AND SUBCOMMITTEES**

CHAIR ANDERSON: Okay. So, let's move on to updates from work groups and subcommittees for the new members listening in, most of the work that we do is done through smaller work groups and subcommittees of the Board to look at the specific sites as well as specific issues. So, you'll get a list of those if you haven't already, and if you're interested in some specific ones, let us know what -- Rashaun and I know, and we'll see -- because we do have a few holes to fill in some of these committees to add members. And we'll be moving to do that as soon as all the paperwork is caught up for the new members.

So, let me begin. As I said, we have had a number of committee meetings. One -- let me start with the one that I chair, and that is the special exposure cohort issues group that had a number of white papers that had been developed by NIOSH. And the issues that we've been addressing is the co-exposure model development. And there are nine sites, I believe, that have co-exposure models being developed for use in dose reconstruction. And one of the issues that has come up that these -- in our discussions have been over -- is the completeness of those data sets, and there typically is some data available, and the question is, is that adequate for developing an exposure model.

Another paper that we reviewed is looking at the use of the NOCTS dataset. And for the new Board members, that's the dataset of all of the individuals who have applied for compensation and have their dose

reconstruction data -- exposure data in a database. And so, looking at whether that can be used to develop co-exposure models to estimate exposures of individuals who otherwise don't have measurement data of their own.

So, part of our discussion also talked about the issue of timeliness, that, as I say, these models are under development, and the question is, do we need or should we -- many of them have been in the works for quite some time. There's always been an issue of site specific -- new data coming in or being found, as Lori just indicated, data was found that resulted in them certifying for review a site. So, trying to balance this new data and new information being developed that we then have to have reviewed to see whether it can be used to develop exposure for individuals or not.

So, many of these sites have had these -- have been under consideration for quite some time, and the question is, we have no criteria, really, for determining how long we should allow for the development of those co-exposure models. So, that's one of the issues that we will be taking up with our group. And I just want the other members of the Board who are not on our work group to think about the timeliness issue. It's one of the things that the petitioners -- was raised and has been problematic. And a lot of this takes quite a bit of time. And of course, with the shutdowns and the other issues, it's been drawing out some of these a little longer than usual. So, that's my report on our group. We will be meeting again to get everything caught up to speed.

So, other chairs have reports?

MEMBER CLAWSON: Yeah, Henry, this is Brad.

CHAIR ANDERSON: Go ahead.

MEMBER CLAWSON: Okay. So, on my side, we just had a work group meeting for Pinellas. Dr. DeGarmo has given us some new information that we have provided the NIOSH and SC&A. SC&A is reviewing this new documentation that was brought in to us, and they're going to give us an evaluation of where we're at on that one. So, we'll have to wait until SC&A does (sic) an official white paper to us, and then we'll pick up and go from there.

I have a work group meeting scheduled for March 17th, I believe it is, for Savannah River. This one, we're just looking at the cutoff date for the SEC, which is, give or take, a few years. It shouldn't be too much more on that.

But what you were just talking about, Andy, you know, I've got a heartache on this, because I'm looking at Hanford over nine years now, and I think that I'm going to be requesting that we get the work group together and proceed on and if -- if it's -- if the cohort -- they can't -- they can't produce this. I've said this before. This is not a science project. This is a compensation program. We're way over date on a lot of these. I want to push this through, so I'll be pushing through to be able to get a Hanford work group back together and be able to proceed on with it and see where we go from there.

Other than that, that's all I have to say. Is there any questions?

CHAIR ANDERSON: Nope, thanks a lot.

Are there -- I think those Pinellas and the SEC work group, I think are the only two, Rashaun, that met --

MEMBER BEACH: No, --

CHAIR ANDERSON: -- recently --

MEMBER BEACH: -- Andy. Andy, this is Josie.

CHAIR ANDERSON: Okay. Go --

MEMBER BEACH: This is Josie.

CHAIR ANDERSON: -- ahead.

MEMBER BEACH: -- that -- I was just going to do a really brief update for the subcommittee. We met the day before Pinellas. So, we met in -- on January 28th. We had a full day's meeting. Kathy, with SC&A, is re -- putting a report together for our next board meeting, and it will kind of explain a little bit about what our procedures work group does, and we'll go through some more of our back data to get those worked on closing out. And our next meeting for the subcommittee is -- tentative meeting, I should say, is June 5th.

We also met -- LANL met, but it was back in December, and LANL is currently scheduled for an April 24th -- tentatively scheduled, I should say. And that one we are working on several reports, but it's for the years 1996 to 2000, so it kind of falls into what the SEC group was talking about last week, just those small -- small amount of years. But we've been working at them for many years. So those -- those are coming -- coming up.

Thanks, Andy.

CHAIR ANDERSON: Okay. Thanks. Any other reports?

Rashaun, did we miss any?

DR. ROBERTS: I believe there was a meeting of Idaho National Laboratory (INL), INL/ANL, Argonne West (ANL), whether Dr. Ziemer wanted

to give a report.

CHAIR ANDERSON: Paul, you're on mute if...

### **PLANS FOR THE APRIL 2026 BOARD MEETING**

CHAIR ANDERSON: Okay. Well, let's move on then to the Board meeting for April.

DR. ROBERTS: Yes, so thank you, Andy. So, this is the planning for, as I mentioned, the full Board meeting, which will be conducted virtually on Teams. It is tentatively scheduled for April 29th and 30th. And just as a reminder, all of the dates that are mentioned for future meetings are, for the most part, tentative. We still have to get approval for them.

But we do need to start identifying content for the meeting. And so, just in terms of standing items, you know, we typically have a NIOSH program update that's done by the DCAS director. There is typically a DOL and -- update as well as a DOE update, and then there is an SEC petition status update that typically goes on the agenda. Standing items also include a Board work session and also the public comment session. So, those will be the standing items for the upcoming agenda. And so, I wanted to throw out and see in terms of work groups and subcommittees, you know, what -- what would you like to present, if at all, and how much time do you need for your presentation. So, I throw that out to the Board.

MEMBER BEACH: This is Josie. I think we probably -- and Kathy, correct me if I'm wrong -- would need about an hour and a half.

DR. ROBERTS: Okay.

MS. BEHLING: This is Kathy -- this is Kathy Behling. I think an hour

and a half will be ample, yes. Both SC&A and DCAS will be making a presentation during that time.

DR. ROBERTS: Okay. So, and what --

MEMBER ZIEMER: (Indiscernible) --

DR. ROBERTS: -- should we name that -- I -- I'm sorry, --

### **UPDATES FROM WORK GROUPS AND SUBCOMMITTEES RESUMING**

MEMBER ZIEMER: This is Paul. Can --

DR. ROBERTS: Yes, I can --

MEMBER ZIEMER: -- you hear me?

DR. ROBERTS: -- hear.

MEMBER ZIEMER: Okay.

DR. ROBERTS: Yeah.

MEMBER ZIEMER: -- having trouble. I was having trouble unmuting. I've been fiddling with that mute button and the star six, and it wouldn't unmute. So, I can report -- I can report now in the Argonne West, if you want me to.

CHAIR ANDERSON: Sure, go ahead.

MEMBER ZIEMER: Am I okay? Should I go ahead?

CHAIR ANDERSON: Yes.

MEMBER ZIEMER: Okay. So, the Argonne -- incidentally, I'll just mention, to everyone, Argonne West is now officially part of Idaho National Laboratory, but we have still a separate Argonne West work group as well as an INL work group. So, the work groups are actually separate. Anyway, Argonne West work group met on December 17th. Currently looking at the

(indiscernible) of -- of -- NOCTS document -- if I can remember the number of it -- the document 054 -- 0054 -- OTIB-0054 -- yeah, I'm sorry. It's OTIB document that has -- has the opportunity of being used (indiscernible) --

I'm hearing a lot of background noise again.

DR. ROBERTS: Can -- yeah. Can people put their phone on mute? I can hear a lot of interference.

MEMBER ZIEMER: Okay. Is that better? Are we --

DR. ROBERTS: Yes.

MEMBER ZIEMER: -- clear now? Okay.

MEMBER CLAWSON: Yes, Paul, that's good.

DR. ROBERTS: Yeah.

MEMBER ZIEMER: Anyway, so NIOSH has been working on the use of OTIB-0054 to determine whether we can have claimant favorable internal doses when you only have gross gamma or gross beta data available. And SC&A's done some reviews on that as well. There -- it looks like a possibility, but we'll report on -- more detail, I think, at the full Board meeting on the status of that and give you an update. But anyway, we are in process of looking at those issues right now for those reactor sites at Argonne West. I think that's enough for today.

DR. ROBERTS: Okay. Paul, thank you so much.

Plans for the April 2026 Board Meeting Resuming

DR. ROBERTS: So, we want an agenda item for Argonne West. And how much time were you thinking for that?

MEMBER ZIEMER: I don't think we need more than 30 minutes. I -- I would say that'd be enough. We'll just do a summary, I think, at this time.

I don't think there'll be any Board action, but we need to update the Board on what's being done. And let -- let me ask -- let's see, I'm thinking Bob Barton, were you involved in the SC&A report, I guess? Is it --

MR. BARTON: Yeah, this is Bob. I think that's accurate. I mean, essentially, we'd be --

MEMBER ZIEMER: I see it. Yeah.

MR. BARTON: -- we're not going to get reactive physics of it.

MEMBER ZIEMER: Well, I think -- I think --

MR. BARTON: -- bring the Board up to speed.

MEMBER ZIEMER: Steve Ostrow may have done the report, but between you and Steve, maybe we can work out a brief summary for us.

MR. BARTON: Sure, yeah, --

DR. OSTROW: Hi, Paul.

MR. BARTON: -- I think -- I think 30 minutes is probably going to be ample.

MEMBER ZIEMER: Yeah, thank you.

DR. ROBERTS: Okay. So, this would just be an item where you, Dr. Ziemer, and SC&A would be presenting, and the no presentation from -- from DCAS?

MEMBER ZIEMER: DCAS may want to -- I -- I think we'll have to take a look at that. DCAS has presented their data, and they -- since DCAS has some follow up, they're going to do -- one of the issues was we can certain - - it looks like we can bound, but there may be cases where the bounding is so high that it is also not that realistic. So, there are some other issues to be looked at, and I don't know, NIOSH, if you think about that too and at

least be prepared to comment. But between Bob, Steve, we'll work out a brief summary of what we have from the Board's point of view.

DR. ROBERTS: Okay.

MS. MARION-MOSS: Hi, Rashaun and Dr. Ziemer. I've made note of that --

MEMBER ZIEMER: Thank you.

MS. MARION-MOSS: -- for INL.

MEMBER ZIEMER: Yeah.

DR. ROBERTS: Okay. Great. All right. Any other -- so, so far, we have subcommittee on procedures review that will -- that has an agenda item and Argonne West. Are there other agenda items we want to put on here?

MEMBER CLAWSON: Rashaun, this is Brad. After our work group meeting for Savannah River, we probably only have a 30 minute -- well, probably an hour to be able to put forth what we come up with, with the Savannah River site. We've just got a little bit of -- we've got some time at the very end of it that we need to bring forth to the full Board, and after this meeting coming up, I think we'll be able to do that.

Steve, I guess, one of the things I'd ask you is, on Pinellas, you think that we're going to have a white paper before then, or -- or what?

DR. OSTROW: Hi, Brad. No, we're not going to have a white paper because the production deadline and all that, we'd have to have the paper due, you know, finished in the next couple of weeks, which it won't happen.

MEMBER CLAWSON: Okay. So, that sounds good. Okay. Yeah. But that -- we'll -- we'll probably just give updates like we do on everything else

for Pinellas and some of the other sites. I just want to make sure. So, that should -- we should have some for Savannah River to be able to go from there, Rashaun.

DR. ROBERTS: Okay. Just to clarify with Pinellas, were you thinking that you'd do an update during the Board work session, or did you want an agenda item?

MEMBER CLAWSON: I -- I think just during the Board work session to bring --

DR. ROBERTS: Okay.

MEMBER CLAWSON: -- the full Board up to speed.

DR. ROBERTS: Okay. Great. Okay. Anything else in terms of work groups or subcommittees to have an agenda item for?

CHAIR ANDERSON: I think for the SEC group, we'll probably just have -- during the work session, because I think we have some reviews that are being done, and we won't have had time to have additional meetings necessarily.

DR. ROBERTS: Okay.

CHAIR ANDERSON: Bob?

MR. BARTON: Well, we -- it was talked about during -- hopefully everybody can hear me. Part of what was talked about during the SEC work group was that it might be beneficial, especially for the newer Board members, to sort of bring them at least up to speed on the discussions that we've been having that were mentioned earlier, you know, about completeness and really just how co-exposure models are constructed within this program and how that works, fundamentally. So, I -- I think it may be

beneficial in April to, again, sort of -- I just really -- just go over giving both SC&A and DCAS a chance to present their views on how these co-exposure models are constructed, which is really the fundamental question for any SEC discussion. It may be beneficial to have sort of a primer, sort of, presentation, which I -- I -- I would guess, you know, at SC&A might need, you know, 45 minutes, maybe. And I'm not sure -- I don't want to speak for DCAS, but I think it -- it would be beneficial to put that on the agenda, if possible.

MEMBER CLAWSON: Hey, Andy, --

CHAIR ANDERSON: Yeah, I think kind of a --

MEMBER CLAWSON: -- this is Brad.

CHAIR ANDERSON: -- I like the primer pre -- you know idea --

MEMBER CLAWSON: Andy, --

CHAIR ANDERSON: -- for that.

MEMBER CLAWSON: -- this is Brad. I -- I just want to make sure, you know, if you think about in the past, this is -- this is a very hot topic, and I think that it would be very beneficial to be able to have this so the new Board members and everything else will get a little bit of the background. I myself -- I would basically set aside a couple of hours to be able to review this and to be able to discuss this in a full Board meeting like that. And like what SC&A said, do kind of little primer, but also give NIOSH chance to -- to talk too. So, I think it'd be really important to be able to have that set up. I -- I'd set aside a couple of hours at least.

CHAIR ANDERSON: Okay. That -- yeah.

MR. BARTON: Okay. Based on --

UNIDENTIFIED SPEAKER: (Indiscernible) --

MR. BARTON: -- discussions when during the SEC issues work group meeting, I think Brad might be on point on that, because there was a lot of good discussions that happened that I think are worthwhile for the full Board to hear.

MEMBER CLAWSON: This -- this is Brad. I -- it's just -- this has been a hot topic at every work group meeting and every Board meeting too. And so, that's why I feel that this is important to get it out there, give the -- the new members an opportunity to be able to understand and see where -- part of where issues are and what we're trying to work through. So, I -- I -- I would really like to see that myself.

DR. ROBERTS: Okay. And --

CHAIR ANDERSON: And I -- I -- I would agree with that. Rashaun?

DR. ROBERTS: Oh, I was just going to check in and see about DCAS --

CHAIR ANDERSON: Yeah.

DR. ROBERTS: -- and whether they want presentation time, just so I can sort of estimate the amount of time for -- for that.

DR. ULSH: Well, this is Brant Ulsh. What I think I heard was you're going to set aside two hours for the SEC issues, and both SC&A and DCAS will present. SC&A is estimating 45 minutes.

DR. ROBERTS: Uh-huh.

DR. ULSH: I suppose I can target 45 minutes as well. I guess for Dr. Anderson, do you think what we're looking for here is kind of building off the presentation that I gave at the SEC issues work group meeting on data

completeness, and then also add on to that just some basics about how coworker models are developed? Is that kind of what we're looking for here?

CHAIR ANDERSON: I would say yes. I -- I think, again, with four new members, give kind of the background on how you go about the coworker models, which ones you're working on, and -- and how they're being used, and then the completeness issue. And, you know, yeah, I think --

DR. ULSH: Okay.

CHAIR ANDERSON: That's what I would think. I mean, April is not that far away.

DR. ULSH: Right.

CHAIR ANDERSON: But I think you probably have most of us already together, it's just bringing everybody up to speed.

DR. ULSH: Okay. So, Bob, that's -- that's what I'll plan on, if you want to plan yours so that we don't say the same thing twice?

MR. BARTON: Yeah. I know what that means, Brant. Yeah. No, and again, I think this is going to be even more high-level look at it just, again, as a -- as a more primer. I don't think we're going to solve everything in April.

DR. ULSH: Okay. Sounds good. Thanks.

DR. ROBERTS: Okay. Thank you. Any items that we may have missed?

MEMBER CLAWSON: Hey, Rashaun, this is just Brad. I'd just -- while we've got Brant on there, I just want to make sure he got my email that I sent. And I'm just wondering where that documentation for Pinellas would

be, they told me they had that I wanted to review. Do I have a time frame for that?

DR. ULSH: Yeah, Brad, I know that --

DR. ROBERTS: Well, --

DR. ULSH: Oh. Go ahead, Rashaun, or anybody.

DR. ROBERTS: I was just thinking that, you know, we're -- we're -- that's a little bit specific, if that's something we could address off -- offline, unless, Brant, you have a quick update.

DR. ULSH: No, I'll get -- Brad, I'll get you an answer offline.

MEMBER CLAWSON: Okay. I just --

DR. HUGHES: This is Lara Hughes. This was sent out by email, I think, this week, earlier this week, so you should have received it.

MEMBER CLAWSON: Well, that's part of the deal. Probably 10 to 1, you sent it to my government email that I don't have access. When I put it in there, I wanted to make sure that -- that's why I brought the question up, Rashaun, is because it's getting -- probably have to be Fed Ex'd to me. So, I just --

DR. ROBERTS: And, again, -- I think this is -- again, Brad, can we talk offline about --

MEMBER CLAWSON: Sure.

DR. ROBERTS: -- all of this?

MEMBER CLAWSON: Sure.

DR. ROBERTS: Thank you.

MEMBER CLAWSON: Yep.

DR. ROBERTS: Any other --

MEMBER CLAWSON: Okay. (Indiscernible) --

DR. ROBERTS: -- agenda items?

CHAIR ANDERSON: No.

DR. ROBERTS: Okay. Andy, let me give it back to you then. Thank you, everybody.

CHAIR ANDERSON: Okay. I have nothing else. Members have anything else they want to bring up, if not --

MEMBER CLAWSON: Andy, just -- Andy, this is just Brad. I was just wondering if we kind of had a time frame for these new Board members to be able to talk.

CHAIR ANDERSON: Yeah.

MEMBER CLAWSON: Do we have any kind of a time --

CHAIR ANDERSON: Well, I guess, Brad, that's kind of --

DR. ROBERTS: It --

CHAIR ANDERSON: Go ahead, Rashaun.

DR. ROBERTS: I'm sorry. Brad, as I said, we're in the process of buttoning up some things before they can fully participate, and I'm expecting that that should be done in fairly short order.

MEMBER CLAWSON: Okay.

CHAIR ANDERSON: Okay. Anything else? Did I have a motion to adjourn?

MEMBER FRANK: Motion to adjourn.

CHAIR ANDERSON: Anyone object? Okay. With that, I want to thank everybody, and we're getting closer to full action, in the -- like we did in the past with the Board. So, I think we're -- we're making progress. It's been

perhaps slower than most of us would have liked, but we're on a track now I think that's going to be implementable, and hopefully NIOSH staffing will also begin to grow, and everything will be back on priority order. So, with that, I'm going to adjourn the meeting.

(Whereupon, the meeting was adjourned at 12:10 p.m. EST.)